Previous 10 | Next 10 |
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the virtual H.C. Wainwright BioConnect 2021 Conference. The fireside chat will ...
Today, we circle back on small oncology concern Verastem for the first time in over three months. The company has posted quarterly results and also some additional trial data since our last update. A fully updated investment thesis on Verastem follows in the paragraphs below. ...
Verastem (VSTM) has initiated Phase 2 trial evaluating VS-6766, its RAF/MEK inhibitor, alone and in combination with defactinib, its FAK inhibitor, in KRAS mutant non-small cell lung cancer ((NSCLC)).The first part of the study will determine the optimal regimen of either VS-6766 monothe...
Phase 2 Adaptive Trial Design to Evaluate VS-6766 Alone and in Combination with Defactinib With a Focus on KRAS-G12V Mutations Trial Designed to Address Significant Unmet Medical Need in These Treatment-Resistant Tumors Verastem Oncology to Seek FDA Accelerated Approva...
4 Penny Stocks To Watch Heading Into December 2020 Call them penny stocks , call them micro- or small cap stocks , whichever the nomenclature, the attraction is still the same. People look to trade penny stocks because of their ability to move quickly and produce huge gains....
Are These On Your List Of Penny Stocks To Watch Right Now? What are some top penny stocks to watch for December 2020 ? Many traders are focusing on healthcare, biotech, and many of the epicenter penny stocks . In general, these are companies that are either working toward an unm...
Should These Be On Your List Of Penny Stocks to Buy Right Now? Penny stocks , love them or hate them, are one of the major topics of discussion this year. That’s mainly due to the fact that so many stocks trading above $5 ended up dropping below that threshold early on. Thank...
Titan Pharmaceuticals (TTNP) -15%.Tuniu TOUR -15% on Q3 earnings release.Medigus MDGS -15% on appointment of new finance chief at MedigusECMOHO MOHO -14% on Q3 earnings release.Minerva Neurosciences (NERV) -14% after announcing outcome of Type C meeting with...
Verastem Oncology (VSTM) +5% in premarket after initiation of a Phase 2 trial evaluating VS-6766, a RAF/MEK inhibitor alone and in combination with defactinib, a FAK inhibitor, in patients with recurrent low-grade serous ovarian cancer ((LGSOC)).First part of the study wil...
Previous Data from Investigator-Initiated Phase 1/2 Trial Show Encouraging Response Rates, Durability and a Favorable Safety Profile Phase 2 Adaptive Trial Design to Evaluate VS-6766 Alone and in Combination with Defactinib Verastem to Seek FDA Accelerated Approval, Pe...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...